Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis

Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis

Background: Hepatitis C virus (HCV) infection is associated with more significant morbidity and mortality among dialysis patients than in healthy populations. The fixed-dose tablet (ombitasvir/ paritaprevir/ritonavir) in combination with ribavirin was effective and generally well tolerated in treatm...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Naglaa El-Gendy, Fathiya EL-Raey, Sherif Nassib, Noha Elsadany
Formato: article
Lenguaje:EN
Publicado: Al-Azhar University, Faculty of Medicine (Damietta) 2020
Materias:
direct acting antiviral drugs
end stage renal disease
hepatitis c
viral infection
hemodialysis
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/d77cf999ebbc437a90bbcf7c9a2894ed
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d77cf999ebbc437a90bbcf7c9a2894ed
record_format dspace
spelling oai:doaj.org-article:d77cf999ebbc437a90bbcf7c9a2894ed2021-12-02T15:22:19ZEfficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis2636-41742682-378010.21608/ijma.2020.21730.1068https://doaj.org/article/d77cf999ebbc437a90bbcf7c9a2894ed2020-01-01T00:00:00Zhttps://ijma.journals.ekb.eg/article_70020_927cfca36a94822d5dbc4255f989d904.pdfhttps://doaj.org/toc/2636-4174https://doaj.org/toc/2682-3780Background: Hepatitis C virus (HCV) infection is associated with more significant morbidity and mortality among dialysis patients than in healthy populations. The fixed-dose tablet (ombitasvir/ paritaprevir/ritonavir) in combination with ribavirin was effective and generally well tolerated in treatment of chronic HCV infected patients with end stage renal disease (ESRD) on hemodialysis. However, limited published data are known about the usefulness of this regimen for treatment of HCV patients with ESRD on hemodialysis. Aim of the work: The aim of this study was to evaluate the safety and efficacy of treatment regimen of ombitasvir (OBV) 25 mg /paritaprevir (PTV) 150 mg /ritonavir (RTV) 100 mg plus generic ribavirin (RBV) 200 mg in Egyptian HCV-infected naive patients with ESRD on regular hemodialysis. Patients and methods: A prospective cohort study involved 40 chronic HCV on regular hemodialysis patients, who were eligible for treatment with combined oral antiviral therapy. Results: The results showed that thirty-five patients [35/40(87.5%)] completed 12 weeks of HCV therapy; they had a virological response at end of therapy and sustained virological response. Anemia was the main observed side effect which lead to discontinuation of the treatment in five patients (12.2%). As these patients were not responding to anemia correction measures (blood transfusion, erythropoietin-stimulating agents, and modification of RBV dose). Conclusion: OBV/PTV/RTV plus Ribavirin can be used in treatment of chronic HCV patients with ESRD on regular hemodialysis.Naglaa El-GendyFathiya EL-RaeySherif NassibNoha ElsadanyAl-Azhar University, Faculty of Medicine (Damietta)articledirect acting antiviral drugsend stage renal diseasehepatitis cviral infectionhemodialysisMedicine (General)R5-920ENInternational Journal of Medical Arts, Vol 2, Iss 1, Pp 313-319 (2020)
institution DOAJ
collection DOAJ
language EN
topic direct acting antiviral drugs
end stage renal disease
hepatitis c
viral infection
hemodialysis
Medicine (General)
R5-920
spellingShingle direct acting antiviral drugs
end stage renal disease
hepatitis c
viral infection
hemodialysis
Medicine (General)
R5-920
Naglaa El-Gendy
Fathiya EL-Raey
Sherif Nassib
Noha Elsadany
Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
description Background: Hepatitis C virus (HCV) infection is associated with more significant morbidity and mortality among dialysis patients than in healthy populations. The fixed-dose tablet (ombitasvir/ paritaprevir/ritonavir) in combination with ribavirin was effective and generally well tolerated in treatment of chronic HCV infected patients with end stage renal disease (ESRD) on hemodialysis. However, limited published data are known about the usefulness of this regimen for treatment of HCV patients with ESRD on hemodialysis. Aim of the work: The aim of this study was to evaluate the safety and efficacy of treatment regimen of ombitasvir (OBV) 25 mg /paritaprevir (PTV) 150 mg /ritonavir (RTV) 100 mg plus generic ribavirin (RBV) 200 mg in Egyptian HCV-infected naive patients with ESRD on regular hemodialysis. Patients and methods: A prospective cohort study involved 40 chronic HCV on regular hemodialysis patients, who were eligible for treatment with combined oral antiviral therapy. Results: The results showed that thirty-five patients [35/40(87.5%)] completed 12 weeks of HCV therapy; they had a virological response at end of therapy and sustained virological response. Anemia was the main observed side effect which lead to discontinuation of the treatment in five patients (12.2%). As these patients were not responding to anemia correction measures (blood transfusion, erythropoietin-stimulating agents, and modification of RBV dose). Conclusion: OBV/PTV/RTV plus Ribavirin can be used in treatment of chronic HCV patients with ESRD on regular hemodialysis.
format article
author Naglaa El-Gendy
Fathiya EL-Raey
Sherif Nassib
Noha Elsadany
author_facet Naglaa El-Gendy
Fathiya EL-Raey
Sherif Nassib
Noha Elsadany
author_sort Naglaa El-Gendy
title Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
title_short Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
title_full Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
title_fullStr Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
title_full_unstemmed Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
title_sort efficacy of ombitasvir/paritaprevir/ritonavir plus ribavirin in treatment of chronic hepatitis c patients with end stage renal disease on regular hemodialysis
publisher Al-Azhar University, Faculty of Medicine (Damietta)
publishDate 2020
url https://doaj.org/article/d77cf999ebbc437a90bbcf7c9a2894ed
work_keys_str_mv AT naglaaelgendy efficacyofombitasvirparitaprevirritonavirplusribavirinintreatmentofchronichepatitiscpatientswithendstagerenaldiseaseonregularhemodialysis
AT fathiyaelraey efficacyofombitasvirparitaprevirritonavirplusribavirinintreatmentofchronichepatitiscpatientswithendstagerenaldiseaseonregularhemodialysis
AT sherifnassib efficacyofombitasvirparitaprevirritonavirplusribavirinintreatmentofchronichepatitiscpatientswithendstagerenaldiseaseonregularhemodialysis
AT nohaelsadany efficacyofombitasvirparitaprevirritonavirplusribavirinintreatmentofchronichepatitiscpatientswithendstagerenaldiseaseonregularhemodialysis
_version_ 1718387423482740736

Ejemplares similares